MCM
SNOA icon

MAI Capital Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

MAI Capital Management’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-124
Closed -$482 – 4471
2025
Q3 		$482 Buy
+124
New +$488 ﹤0.01% 3630

Other funds holding SNOA

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

MAI Capital Management's SNOA Position: Q4 2025 in Review

MAI Capital Management sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2025, closing a stake of 124 shares — an estimated $482 sold.

MAI Capital Management first reported a position in SNOA in Q3 2025 and held it in 1 quarter. The position peaked at $482 in Q3 2025. 16 funds tracked by Wall St. Rank hold SNOA as of Q4 2025.

  • MAI Capital Management reported no remaining Sonoma Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • MAI Capital Management sold 124 Sonoma Pharmaceuticals shares in Q4 2025, an estimated $482.
  • MAI Capital Management first reported a position in Sonoma Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • MAI Capital Management's Sonoma Pharmaceuticals position peaked at $482 in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2025.

Based on MAI Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.